Medicare AdvantageCoverageMedium impact
MA06.017aa, Molecular Diagnostics
Independence Blue Cross·Oncology, Pathology·Medical Policy
Effective date
Apr 29, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA06.017aa for Molecular Diagnostics has been reissued with an effective date of April 29, 2026. This is a policy update that may contain changes to coverage criteria, billing requirements, or prior authorization rules for molecular diagnostic testing under Medicare Advantage plans.
Action Required
By April 29, 2026: Billing team must review the complete MA06.017aa Molecular Diagnostics policy at the provided URL to identify specific changes to coverage criteria, prior authorization requirements, or billing procedures for molecular diagnostic tests. Update billing system and encounter forms based on any new requirements found in the full policy.